Vaccine
OwnerJose Luis Toran Garcia, Carlos Martinez Alonsoinventors
Life of this patent
Estimating the term…
Abstract
The application relates to antibodies and fragments capable of binding HIV-1 gp120 protein, nucleic acids encoding such proteins, to the use of such proteins to identify active compounds, and to the use of the compounds as vaccines.
Claims24
An antibody or a fragment thereof comprising a light chain and/or a heavy chain, the light chain or heavy chain comprising the amino acid sequence shown in SEQ ID 2, SEQ ID 4, SEQ ID 6 or SEQ ID 8, which is capable of binding gp120 protein from HIV.
An antibody or a fragment thereof comprising a light chain and a heavy chain, the light chain comprising the amino acid sequence shown in SEQ ID 2 and the heavy chain comprising an amino acid sequence selected from SEQ ID 4, SEQ ID 6 and SEQ ID 8, the antibody or fragment being capable of binding gp120 protein from HIV.
A nucleic acid molecule selected from:
- (a) a nucleic acid molecule which encodes for an antibody or a fragment of an antibody according to any preceding claim;
- (b) a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID 1 and optionally one of SEQ ID3, SEQ ID5 or SEQ ID 7:
- (c) a nucleic acid molecule, the complementary strand of which hybridises to a nucleic acid molecule as defined in (a) or (b) and which encodes an antibody or a fragment of an antibody light chains and which is capable of binding gp120 protein from HIV;
- and
- (d) nucleic acid molecules which differ from the sequence of (c) due to the degeneracy of the genetic code.
A chemical compound identifiable by a method according to claim 10.
An isolated peptide comprising an amino acid sequence which encodes for one or both of regions Ile420-Gln422 and/or Pro437-Pro438 of the gp120 protein of HIV.
Dependencies are inferred from the claim text.